Targeted Therapy in Acute Lymphoblastic Leukaemia.

J Pers Med · 2021 · PMC8398498 · PMID 34442359

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In the context of this reduced sample size, the addition of bortezomib was associated with a trend toward improved three-year EFS (85.1% versus 81.7%, p = 0.0736) and OS (88.2% versus 85.5%, p = 0.087) but failed to reach statistical significance [ 107 ].

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.